Bloomberg Anywhere Login


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Last $10.71 USD
Change Today +0.28 / 2.68%
Volume 865.3K
ANTH On Other Exchanges
As of 8:10 PM 08/4/15 All times are local (Market data is delayed by at least 15 minutes).

anthera pharmaceuticals inc (ANTH) Snapshot

Previous Close
Day High
Day Low
52 Week High
07/24/15 - $11.65
52 Week Low
12/23/14 - $1.46
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield

anthera pharmaceuticals inc (ANTH) Related Bloomberg News

View More Bloomberg News

anthera pharmaceuticals inc (ANTH) Related Businessweek News

No Related Businessweek News Found

anthera pharmaceuticals inc (ANTH) Details

Anthera Pharmaceuticals, Inc., a biopharmaceutical company, focuses on developing and commercializing medicines for patients with unmet medical needs. It is developing blisibimod, a Phase III product candidate that targets B-cell activating factor associated with various B-cell mediated autoimmune diseases, including systemic lupus erythematosus, Immunoglobulin A nephropathy, lupus nephritis, and others. The company is also developing a Phase III product candidate Liprotamase, a non-porcine investigational pancreatic enzyme replacement therapy intended for the treatment of patients with exocrine pancreatic insufficiency. Anthera Pharmaceuticals, Inc. was founded in 2004 and is headquartered in Hayward, California.

20 Employees
Last Reported Date: 03/16/15
Founded in 2004

anthera pharmaceuticals inc (ANTH) Top Compensated Officers

Chief Executive Officer, President and Direct...
Total Annual Compensation: $515.0K
Principal Accounting Officer, Compliance Offi...
Total Annual Compensation: $261.0K
Chief Medical Officer and Senior Vice Preside...
Total Annual Compensation: $350.0K
Chief Technology Officer and Senior Vice Pres...
Total Annual Compensation: $340.0K
Chief Regulatory Officer and Senior Vice Pres...
Total Annual Compensation: --
Compensation as of Fiscal Year 2014.

anthera pharmaceuticals inc (ANTH) Key Developments

Anthera Pharmaceuticals, Inc.(NasdaqGM:ANTH) added to Russell 2000 Index

Anthera Pharmaceuticals, Inc. will be added to Russell 2000 Index

Anthera Pharmaceuticals, Inc.(NasdaqGM:ANTH) added to Russell 3000 Index

Anthera Pharmaceuticals, Inc. will be added to the Russell 3000 Index.

Anthera Pharmaceuticals, Inc. Reaches Enrollment Target in CHABLIS-SC1 Phase 3 Clinical Trial with Blisibimod

Anthera Pharmaceuticals, Inc. announced that it has met the enrollment target of its CHABLIS-SC1 Phase 3 clinical trial evaluating blisibimod for the treatment of lupus. Final data from the trial is expected in the second half of 2016. Results from CHABLIS-SC1, and eventually CHABLIS-SC2, are anticipated to support marketing approval for blisibimod as a treatment for active SLE that is not controlled by current best practice standard-of-care, including corticosteroids.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
ANTH:US $10.71 USD +0.28

ANTH Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for ANTH.
View Industry Companies

Industry Analysis


Industry Average

Valuation ANTH Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 1,174.8x
Price/Book 10.6x
Price/Cash Flow NM Not Meaningful
TEV/Sales 1,496.7x

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact ANTHERA PHARMACEUTICALS INC, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at